Combining H1-Coil Deep Transcranial Magnetic Stimulation (dTMS) and App-guided CBT in Subjects With Major Depression Disorder (MDD)
- Conditions
- Data Collection for Facilitation of Machine Learning Algorithm for Personalized Treatment
- Registration Number
- NCT04455646
- Lead Sponsor
- Brainsway
- Brief Summary
A naturalistic study design, in which dTMS patients will be randomized to get a free add-on CBT treatment. The dTMS procedure will include treatment as usual, and participants will use the app from post randomization (Pre-treatment is defined as measures from the first three days of treatment) to the end of dTMS treatment (Post-treatment which is defined as measures from after twenty TMS sessions over a minimum of four weeks), and for an additional three months of FU (FU).
- Detailed Description
Participants will be recruited from those attending dTMS clinics around the world (i.e.,naturalistic study design), and consenting individuals (in person consent done in the clinic on paper) will be given a random user code. This code will be specific for their version of the app, and the only link between their signature and the code will remain at the site for auditing purposes. Participants will undergo treatment as usual of dTMS and will use GGDE twice a day. Participants will be asked to complete demographic and clinical questionnaires via the GGDE app, and relevant clinical questionnaires will be re-administered following treatment and during FU. The initial and all following dTMS sessions will involve patients going through the stimulation procedure (The operator will record stimulation variables such as individual patient's intensity of stimulation and coil location into GGDE) followed by 5 min of GGDE use. The patient will indicate which statements (in that session) were most relevant and challenging to them, which will be followed by a pre-prepared psycho-education paragraph about the specific maladaptive belief addressed by the app that day. The patient will then be prompted to use the app one more time at home during the same day. Patient will continue similar use during FU, with two GGDE usage each day. The naturalistic design will allow the accumulation of large quantities of data in a short period of time, aiming to optimize GGDE using machine learning. Importantly, GGDE will allow the random allocation of users to different GGDE modules of the app (i.e., similar app versions with changes in specific parameters related to different depressive traits). One out of the ten modules used in this trial will include neutral (placebo) stimuli requiring the user to respond to plus/minus signs rather than MDD relevant statements.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 540
- Adult outpatients accepted to treatment as usual dTMS with a Primary DSM-V diagnosis of Major Depression, single or recurrent episode
- Capable and willing to provide informed consent
- In a possession of a Smartphone capable of running the GGDE app.
- Able to adhere to the treatment schedule.
Investigators, site personnel directly affiliated with this study, and their immediate families (immediate family is defined as a spouse, parent, child or sibling, whether by birth or legal adoption).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patient Patient Health Questionnaire (PHQ) Patient Health Questionnaire (PHQ) Patient Health Questionnaire (PHQ) Health Questionnaire (PHQ) 1 year The change from Pre- to Post-treatment in the Patient Health Questionnaire (PHQ) scores from baseline to endpoint.
- Secondary Outcome Measures
Name Time Method Patient Patient Health Questionnaire (PHQ) 1 year Response rate (50% reduction from Pre-treatment of the PHQ score), where the rate refers to the percentage of patients in response at Post-treatment.
* Remission rate (PHQ\<5; \[1\]), where the rate refers to the percentage of patients in remission at Post-treatment,
* Response rate, Remission rate, and the change from Pre-treatment to FU in the PHQ score.
Trial Locations
- Locations (22)
Kadima Neuropsychiatry
🇺🇸San Diego, California, United States
Advanced Mental Health Care Inc. - Juno Beach
🇺🇸Juno Beach, Florida, United States
Advanced Mental Health Care Inc. - Palm Beach
🇺🇸Palm Beach, Florida, United States
Greenbrook - Columbia
🇺🇸Columbia, Maryland, United States
Greenbrook - Annapolis
🇺🇸Annapolis, Maryland, United States
Greenbrook - Frederick
🇺🇸Frederick, Maryland, United States
Advanced Mental Health Care Inc. - Royal Palm Beach
🇺🇸Royal Palm Beach, Florida, United States
Greenbrook - Glen Burnie
🇺🇸Glen Burnie, Maryland, United States
Greenbrook - Greenbelt
🇺🇸Greenbelt, Maryland, United States
Greenbrook - Kensington
🇺🇸Kensington, Maryland, United States
Greenbrook - Tesson Ferry
🇺🇸Saint Louis, Missouri, United States
Greenbrook - Olney
🇺🇸Olney, Maryland, United States
Greenbrook - Creve Coeur
🇺🇸Saint Louis, Missouri, United States
Greenbrook - Greensboro
🇺🇸Greensboro, North Carolina, United States
Greenbrook - Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
Greenbrook - Matthews
🇺🇸Matthews, North Carolina, United States
Greenbrook - Raleigh
🇺🇸Raleigh, North Carolina, United States
Greenbrook TMS NeuroHealth Centers
🇺🇸McLean, Virginia, United States
Greenbrook - Glen Allen
🇺🇸Glen Allen, Virginia, United States
Greenbook - Newport News
🇺🇸Newport News, Virginia, United States
Greenbrook - Rockville
🇺🇸Rockville, Maryland, United States
Greenbrook - O'Fallon
🇺🇸O'Fallon, Missouri, United States